{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.0","upperLimit":"39.4","value":"30.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"}],"units":"Participants"}],"description":"Durable response is defined as an objective response (confirmed complete response \\[CR\\] or confirmed Partial response \\[PR\\]) according to Response Evaluation Criteria in Solid Tumors version (RECIST) 1.1, determined by the Independent Endpoint Review Committee (IERC), with a duration of at least 6 months. The DRR was determined as the percentage of participants with an objective response in terms of CR or PR according to RECIST 1.1, as determined by the IERC, with a duration of at least 6 months. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part B: Avelumab"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS) included all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 161 weeks","title":"Part B: Durable Response Rate (DRR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}